Neuroprotective effects of edaravone on cognitive deficit, oxidative stress and tau hyperphosphorylation induced by intracerebroventricular streptozotocin in rats

NeuroToxicology

Volumn 38, Issue , 2013, Pages 136-145

  Zhou, Shanshan ^a   Yu, Guichun ^a   Chi, Lijun ^a   Zhu, Jiwei ^b   Zhang, Wei ^b   Zhang, Yan ^a   Zhang, Liming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Edaravone; Oxidative stress; Streptozotocin; Tau hyperphosphorylation

Indexed keywords

4 HYDROXYNONENAL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; MALONALDEHYDE; NORPHENAZONE; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY EQUILIBRIUM; BRAIN CORTEX; COGNITIVE DEFECT; CONTROLLED STUDY; HIPPOCAMPUS; LATENT PERIOD; MALE; MAZE TEST; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; PROTEIN PHOSPHORYLATION; RAT;

EDARAVONE; OXIDATIVE STRESS; STREPTOZOTOCIN; TAU HYPERPHOSPHORYLATION;

ALZHEIMER DISEASE; ANIMALS; ANTIPYRINE; COGNITION DISORDERS; FREE RADICAL SCAVENGERS; INFUSIONS, INTRAVENTRICULAR; MALE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PHOSPHORYLATION; RATS; STREPTOZOCIN; TAU PROTEINS;

EID: 84883044650     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2013.07.007     Document Type: Article

References (51)

1. Adolphs R. Neural systems for recognizing emotion. Curr Opin Neurobiol 2002, 12(2):169-177. [PubMed: 12015233].
2. Ansari M.A., Scheff S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 2010, 69(2):155-167. [PubMed: 20084018].
3. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience 2001, 102(4):723-765. [PubMed: 11182240].
4. Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992, 42(3 Pt 1):631-639. [PubMed: 1549228].
5. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004, 3(3):205-214. [PubMed: 15031734].
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. [PubMed: 942051].
7. Chen S., Liu A.R., An F.M., Yao W.B., Gao X.D. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4. Age (Dordr) 2012, 34(5):1211-1224. [PubMed: 21901364].
8. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000, 71(2):621S-629S. [PubMed: 10681270].
9. Clausen A., Xu X., Bi X., Baudry M. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline. J Alzheimers Dis 2012, 30(1):183-208. [PubMed: 22406441].
10. Coppieters N., Dragunow M. Epigenetics in Alzheimer's disease: a focus on DNA modifications. Curr Pharm Des 2011, 17(31):3398-3412. [PubMed: 21902668].
11. Correia S.C., Santos R.X., Santos M.S., Casadesus G., Lamanna J.C., Perry G., et al. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease. Curr Alzheimer Res 2012, [PubMed: 23061885].
12. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004, 101(7):2070-2075. [PubMed: 14970312].
13. Dringen R., Gutterer J.M., Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur J Biochem 2000, 267(16):4912-4916. [PubMed: 10931173].
14. Dringen R., Pawlowski P.G., Hirrlinger J. Peroxide detoxification by brain cells. J Neurosci Res 2005, 79(1/2):157-165. [PubMed: 15573410].
15. Dumont M., Stack C., Elipenahli C., Jainuddin S., Gerges M., Starkova N.N., et al. Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J 2011, 25(11):4063-4072. [PubMed: 21825035].
16. Fang Y.Z., Yang S., Wu G. Free radicals, antioxidants, and nutrition. Nutrition 2002, 18(10):872-879. [PubMed: 12361782].
17. Grunblatt E., Salkovic-Petrisic M., Osmanovic J., Riederer P., Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 2007, 101(3):757-770. [PubMed: 17448147].
18. Hanger D.P., Anderton B.H., Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 2009, 15(3):112-119. [PubMed: 19246243].
19. Ishrat T., Hoda M.N., Khan M.B., Yousuf S., Ahmad M., Khan M.M., et al. Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer's type (SDAT). Eur Neuropsychopharmacol 2009, 19(9):636-647. [PubMed: 19329286].
20. Ishrat T., Parveen K., Khan M.M., Khuwaja G., Khan M.B., Yousuf S., et al. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type. Brain Res 2009, 1281:117-127. [PubMed: 19374888].
21. Ito H., Wate R., Zhang J., Ohnishi S., Kaneko S., Nakano S., et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 2008, 213(2):448-455. [PubMed: 18718468].
22. Kaur C., Ling E.A. Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem 2008, 15(29):3068-3080. [PubMed: 19075654].
23. Kikuchi K., Kawahara K.I., Uchikado H., Miyagi N., Kuramoto T., Miyagi T., et al. Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction. Exp Ther Med 2011, 2(5):771-775. [PubMed: 22977573].
24. Kikuchi K., Takeshige N., Miura N., Morimoto Y., Ito T., Tancharoen S., et al. Beyond free radical scavenging: beneficial effects of edaravone (Radicut) in various diseases. Exp Ther Med 2012, 3(1):3-8. [review; PubMed: 22969835].
25. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795. [PubMed: 17051205].
26. Liu Q., Smith M.A., Avila J., DeBernardis J., Kansal M., Takeda A., et al. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 2005, 38(6):746-754. [PubMed: 15721985].
27. Markesbery W.R. The role of oxidative stress in Alzheimer disease. Arch Neurol 1999, 56(12):1449-1452. [PubMed: 10593298].
28. Mattson M.P. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann NY Acad Sci 2004, 1012:37-50. [PubMed: 15105254].
29. Mattson M.P. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegenerative disorders. Exp Gerontol 2009, 44(10):625-633. [PubMed: 19622391].
30. Melov S., Adlard P.A., Morten K., Johnson F., Golden T.R., Hinerfeld D., et al. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE 2007, 2(6):e536. [PubMed: 17579710].
31. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11(1):47-60. [PubMed: 6471907].
32. Pratico D., Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 2000, 109(7):577-585. [PubMed: 11063960].
33. Ren Q.G., Liao X.M., Chen X.Q., Liu G.P., Wang J.Z. Effects of tau phosphorylation on proteasome activity. FEBS Lett 2007, 581(7):1521-1528. [PubMed: 17376439].
34. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316(5825):750-754. [PubMed: 17478722].
35. Salkovic-Petrisic M., Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl 2007, (72):217-233. [PubMed: 17982898].
36. Salkovic-Petrisic M., Osmanovic-Barilar J., Bruckner M.K., Hoyer S., Arendt T., Riederer P. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer's disease: a long-term follow up study. J Neural Transm 2011, 118:765-772. [PubMed: 21533606].
37. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968, 25(1):192-205. [PubMed: 4973948].
38. Sharma M., Gupta Y.K. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci 2001, 68(9):1021-1029. [PubMed: 11212865].
39. Smith C.D., Carney J.M., Tatsumo T., Stadtman E.R., Floyd R.A., Markesbery W.R. Protein oxidation in aging brain. Ann NY Acad Sci 1992, 663:110-119. [PubMed: 1362341].
40. Smith M.A., Zhu X., Tabaton M., Liu G., McKeel D.W., Cohen M.L., et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 2010, 19(1):363-372. [PubMed: 20061651].
41. Steiner M.G., Babbs C.F. Quantitation of the hydroxyl radical by reaction with dimethyl sulfoxide. Arch Biochem Biophys 1990, 278(2):478-481. [PubMed: 2327799].
42. Su B., Wang X., Nunomura A., Moreira P.I., Lee H.G., Perry G., et al. Oxidative stress signaling in Alzheimer's disease. Curr Alzheimer Res 2008, 5(6):525-532. [PubMed: 19075578].
43. Tabrizchi R. Edaravone Mitsubishi-Tokyo. Curr Opin Investig Drugs 2000, 1(3):347-354. [PubMed: 11249718].
44. Takahashi G., Sakurai M., Abe K., Itoyama Y., Tabayashi K. MCI-186 prevents spinal cord damage and affects enzyme levels of nitric oxide synthase and Cu/Zn superoxide dismutase after transient ischemia in rabbits. J Thorac Cardiovasc Surg 2003, 126(5):1461-1466. [PubMed: 14666020].
45. Tuppo E.E., Forman L.J. Free radical oxidative damage and Alzheimer's disease. J Am Osteopath Assoc 2001, 101(12 Suppl., Pt 1):S11-S15. [PubMed: 11794746].
46. Uttara B., Singh A.V., Zamboni P., Mahajan R.T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 2009, 7(1):65-74. [PubMed: 19721819].
47. Yang Y., Yang X.F., Wang Y.P., Tian Q., Wang X.C., Li H.L., et al. Inhibition of protein phosphatases induces transport deficits and axonopathy. J Neurochem 2007, 102(3):878-886. [PubMed: 17472709].
48. Yoshida H., Yanai H., Namiki Y., Fukatsu-Sasaki K., Furutani N., Tada N. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev 2006, 12(1):9-20. [PubMed: 16834755].
49. Zawia N.H., Lahiri D.K., Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 2009, 46(9):1241-1249. [PubMed: 19245828].
50. Zhang N., Komine-Kobayashi M., Tanaka R., Liu M., Mizuno Y., Urabe T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005, 36(10):2220-2225. [PubMed: 16166574].
51. Zhao H.F., Li Q., Li Y. Long-term ginsenoside administration prevents memory loss in aged female C57BL/6J mice by modulating the redox status and up-regulating the plasticity-related proteins in hippocampus. Neuroscience 2011, 183:189-202. [PubMed: 21463662].